CD19 and cancer: Notably, a pivotal phase I/II trial (NCT03056339) conducted at the MD Anderson Cancer Center demonstrated that CAR-NK cells derived from cord blood could be safely administered to patients with relapsed or refractory CD19-positive cancers, including non-Hodgkin’s lymphoma and chronic lymphocytic leukemia [24].